As a consequence, the HR genes BRCA1, BRCA2, PALB2, RAD51C, RAD51D, BARD1, BRIP1, MRE11, RAD51 and NBN are included in several hereditary breast/ovarian cancer screening panels to evaluate the tumour for HR deficiency and predict its response to chemotherapy (19). The gene discussed is BRCA2; the disease is ovarian carcinoma.